These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 16538529

  • 1. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
    Ingle JN, Suman VJ, Mailliard JA, Kugler JW, Krook JE, Michalak JC, Pisansky TM, Wold LE, Donohue JH, Goetz MP, Perez EA.
    Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
    [Abstract] [Full Text] [Related]

  • 2. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01).
    Belfiglio M, Valentini M, Pellegrini F, De Berardis G, Franciosi M, Rossi MC, Sacco M, Nicolucci A, Interdisciplinary Group for Cancer Care Evaluated (GIVIO) Group.
    Cancer; 2005 Dec 01; 104(11):2334-9. PubMed ID: 16245354
    [Abstract] [Full Text] [Related]

  • 3. [Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial].
    Delozier T, Switsers O, Génot JY, Ollivier JM, Héry M, Namer M, Frenay M, Kerbrat P, Julien JP, Naja A, Janvier M, Macé-Lesec'h J.
    Bull Cancer; 1997 Jan 01; 84(1):25-30. PubMed ID: 9180855
    [Abstract] [Full Text] [Related]

  • 4. [A randomized study of adjuvant treatments for operable breast cancer patients stratified by estrogen receptor and menopausal status].
    Nomura Y, Tsutsui S, Murakami S, Takenaka Y.
    Gan To Kagaku Ryoho; 1999 Apr 01; 26(5):643-9. PubMed ID: 10234295
    [Abstract] [Full Text] [Related]

  • 5. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
    Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, Tausch C, Stöger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M.
    J Clin Oncol; 2012 Mar 01; 30(7):722-8. PubMed ID: 22271481
    [Abstract] [Full Text] [Related]

  • 6. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
    Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R, Greil R, Jelen A, Böhm G, Jasarevic Z, Haid A, Gruber C, Pöstlberger S, Filipits M, Gnant M, Austrian Breast and Colorectal Cancer Study Group.
    Clin Cancer Res; 2011 Dec 15; 17(24):7828-34. PubMed ID: 21998336
    [Abstract] [Full Text] [Related]

  • 7. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.
    Acta Oncol; 2009 Dec 15; 48(4):514-21. PubMed ID: 19107621
    [Abstract] [Full Text] [Related]

  • 8. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE.
    Semin Oncol; 2006 Apr 15; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [Abstract] [Full Text] [Related]

  • 9. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
    Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O'Reilly SE, Wilson CF, Han L, Piura E, Whelan TJ, Pollak MN.
    J Clin Oncol; 2011 Oct 10; 29(29):3869-76. PubMed ID: 21911723
    [Abstract] [Full Text] [Related]

  • 10. Radiation therapy plus tamoxifen versus tamoxifen alone after breast-conserving surgery in postmenopausal women with stage I breast cancer: a decision analysis.
    Punglia RS, Kuntz KM, Lee JH, Recht A.
    J Clin Oncol; 2003 Jun 15; 21(12):2260-7. PubMed ID: 12805324
    [Abstract] [Full Text] [Related]

  • 11. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
    Fargeot P, Bonneterre J, Roché H, Lortholary A, Campone M, Van Praagh I, Monnier A, Namer M, Schraub S, Barats JC, Guastalla JP, Goudier MJ, Chapelle-Marcillac I.
    J Clin Oncol; 2004 Dec 01; 22(23):4622-30. PubMed ID: 15505276
    [Abstract] [Full Text] [Related]

  • 12. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.
    J Clin Oncol; 2007 Feb 10; 25(5):486-92. PubMed ID: 17200148
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Adjuvant endocrine treatment of postmenopausal patients with breast cancer with high risk of recurrence. 5. Results from the DBCG (Danish Breast Cancer Cooperative Group) 77C randomized trial].
    Rose C, Andersen JA, Andersen KW, Axelsson CK, Blichert-Toft M, Dombernowsky P, Hansen M, Krag C, Mouridsen HT, Overgaard M.
    Ugeskr Laeger; 1991 Aug 12; 153(33):2283-7. PubMed ID: 1781047
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis.
    Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, Tschetter LK, Long HJ, Gerstner JG, Windschitl HE.
    Cancer; 1991 Feb 15; 67(4):886-91. PubMed ID: 1991261
    [Abstract] [Full Text] [Related]

  • 20. Adjuvant cyclic Tamoxifen and Megestrol acetate treatment in postmenopausal breast cancer patients--longterm follow-up.
    Fjøsne HE, Jacobsen AB, Lundgren S, Norwegian Breast Cancer Group (NBCG).
    Eur J Surg Oncol; 2008 Jan 15; 34(1):6-12. PubMed ID: 17881183
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.